Remove 2004 Remove FDA Remove Licensing
article thumbnail

Q&A: George Church on Genomics of Cognitive Enhancement

Bill of Health

In these spin-offs, does one approach the Church Lab with a request for licensing or are there collaboration agreements with the Harvard Office of Technology Review? The practicality I’ve noticed over the years is that no matter what we aim at, there’s the very severe, shorter-term FDA trial. GC: Both are possible.

FDA 240
article thumbnail

SQA Regulatory Surveillance Summary | Monthly Update 2022 – September/October

SQA

This proposal builds upon the existing legal framework, which came into force in 2002 for blood and 2004 for tissues and cells. United States Food and Drug Administration (FDA) – Regulations and guidance. The FDA is issuing this guidance to provide clarity and predictability for software manufacturers on this topic.

FDA 40
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

SQA Regulatory Surveillance Summary | Monthly Update 2023 – July and August 2023

SQA

The US FDA has already recognized the ability of 16 EU Member States to conduct GMP inspections of manufacturers of veterinary medicinal products. At the same time, the EU has recognized the US FDA as an equivalent authority to carry out these inspections.

FDA 40
article thumbnail

Health Provider News

Hall Render

Inman College of Nursing FDA clears Collierville startup CircumFix’s medical device for surgery, marketing FTC opposes Novant Health’s $320M hospital deal with Community Health Systems HCA CFO to retire HCA nets $5.2B for Dental Health OakLeaf Medical Network reaches out to HSHS WYOMING Gov.

article thumbnail

Comment K, Presumptions, and Medical Device Design Defects Under Texas Law

Drug & Device Law

2004); and Hackett v. Texas, unlike most states, enforces a strong statutory presumption that prescription medical product warnings complying with FDA requirements imposed by “pre-market approval or licensing of the product” are adequate as a matter of law. March 4, 2005), rev’d on other grounds , 462 F.3d 3d 364 (5th Cir.

FDA 59